Press Release

DKMS Funds Lifesaving Bone Marrow Transplant Unit for Children in India

DKMS has expanded its global impact by funding a new bone marrow transplant unit for pedriatic patients in Ahmedabad, India. This state-of-the-art facility will provide lifesaving treatment to up to 120 children with hereditary blood disorders annually, offering them a second chance at life.

Tübingen, 10 February 2025. On February 7 and 8, 2025, DKMS, globally recognized for managing the world's largest stem cell donor database, partnered with Sankalp India Foundation to celebrate the inauguration of a new BMT facility at Health1 Super Speciality Hospital in Ahmedabad. Designed to meet the growing demand for stem cell transplantations in the region, the new center includes 10 specialized pediatric BMT beds, alongside essential apheresis, care facilities and an outpatient center. More than 26 professionals, including 4 doctors and 14 nurses, will ensure best possible care for patients. The project reflects DKMS's holistic approach to fighting blood cancer and blood disorders by improving access to transplantation in low- and middle-income countries.

Addressing a critical need in India

India faces a pressing healthcare challenge: over 12,000 children are born each year with thalassemia, a hereditary blood disorder that causes severe anemia. These children often require lifelong blood transfusions, and without proper treatment, many do not survive beyond the age of 20. Bone marrow transplantation offers the only curative option, but access remains limited due to financial and logistical barriers.

To bridge this gap, DKMS has teamed up with the nonprofit Sankalp India Foundation to establish the new transplant unit in Ahmedabad. DKMS has committed 31.15 million Indian rupees (approximately 350,000 euros) to fund the initiative, which is managed by Sankalp with medical advisory support from Cure2Children.

"Our goal is to provide sustainable cures for patients in disadvantaged regions by building local capacity and offering support 'in the country, for the country,' " explains Dr. Elke Neujahr, Global CEO of DKMS.

"By funding the BMT unit in Ahmedabad, we are bringing lifesaving care closer to home, reducing barriers to treatment, and supporting families who might otherwise have to travel long distances. We dream of giving every child suffering from thalassemia in India a second chance at life – a chance to smile, grow, and embrace the future they deserve."

Expanding lifesaving access

The new center replaces an older, smaller facility in Ahmedabad that could no longer meet the region's increasing demand for care. It is the second BMT unit in India funded by DKMS, in memory of Mechtild Harf, the late wife of DKMS founder Peter Harf.

The first BMT unit in Bangalore, established in 2021 and also operated by Sankalp in collaboration with Cure2Children, has already had a positive impact on more than 460 children with thalassemia. These efforts are part of DKMS's international Capacity Building Program and its "Access to Transplantation" initiative, aimed at improving conditions for patients in low- and middle-income regions who would otherwise lack access to this lifesaving treatment.

A story of hope: Tanvi

The impact of this initiative is best reflected in the story of Tanvi, a young girl diagnosed with thalassemia at just six months old. Born into a family facing daily financial struggles, her father – an auto-rickshaw driver – worked tirelessly to provide for them. For Tanvi, routine blood transfusions became a lifeline, but as the financial burden grew overwhelming, her father desperately sought help.

Thanks to free HLA typing, funded by DKMS and facilitated by Sankalp, a genetic match – and the foundation for a stem cell transplant – was found: Tanvi's own sister, Dhanvi. With renewed hope, the family accessed the BMT procedure at the former Ahmedabad unit, a turning point in Tanvi's battle against the disease. Today, five years after her transplant, 16-year-old Tanvi is thriving – a joyful child who loves dancing and embraces life with newfound energy.

"I am immensely grateful that my daughter could receive this treatment thanks to DKMS and Sankalp," shares Tanvi's father. "Because of them, I can see her smile again. She now has the chance for a long and full life."

In addition to receiving the transplant, Tanvi's family benefited from DKMS's Patient Funding Program, which helped ease the financial strain of the procedure, ensuring she got the care she needed.

"Our collaboration with DKMS has transformed the lives of more than 570 children in India since 2018," says Rajat Kumar Agarwal, President of Sankalp. "With the new and expanded unit in Ahmedabad, where up to 120 children can be treated every year, even more children can be saved and return to a happy life. It represents hope and a brighter future for families facing the challenges of thalassemia."

Press Contact
Julia Schmitz
DKMS Group – Global Corporate Communications
Press Contact
Fabienne Assmann
DKMS Group – Global Corporate Communications

About Sankalp

Sankalp India Foundation is a nonprofit organization based in Bangalore that is working for the cause of voluntary blood donation and treating children with blood disorders like thalassemia since 2003. Sankalp has set up a network of 23 not-for-profit day care centers across the country where over 2,500 children suffering from blood disorders receive equitable healthcare. The organization has been curing children through blood stem cell transplants on a nonprofit basis in its two centers (Bangalore and Ahmedabad) since 2015 and has organized more than 700 transplants for children in India.

Sankalp is also working on hemoglobinopathies prevention by offering targeted screening for inherited blood disorders for pregnant women. So far, they have tested over 140,000 couples to help identify and manage potential risks early.

About Cure2Children

Cure2Children, is a nonprofit organization, with the mission of bringing cure to children with cancer and severe blood disorders. The organization, based in Florence, Italy, operates globally. It was launched in 2007 by a group of parents who lost their child to cancer, in collaboration with a pediatric hematologist-oncologist, Dr. Lawrence Faulkner. Cure2Children has enabled the set-up of several bone marrow transplant units in low- and middle-income countries across South-East Asia, the Middle East and Africa. To date, 1,300 bone marrow transplants have been performed, primarily severe Thalassemia syndromes in children below the age of 18.

About Health1 Super Speciality Hospitals

Founded in 2017, Health1 Super Speciality Hospitals is a leading healthcare group offering 40+ super-specialty branches across two state-of-the-art facilities in Ahmedabad. With cutting-edge infrastructure, advanced medical technologies, and a patient-centric approach, Health1 provides comprehensive care under one roof, including modern ICUs, modular operation theaters, cath labs, and 24/7 emergency services. Committed to holistic, multidisciplinary healthcare, Health1 prioritizes ethical practices, personalized treatment plans, and affordability.